WallStreetZenWallStreetZen

NASDAQ: VTRS
Viatris Inc Stock Forecast, Predictions & Price Target

Analyst price target for VTRS

Based on 2 analysts offering 12 month price targets for Viatris Inc.
Min Forecast
$13.00+9.8%
Avg Forecast
$14.00+18.24%
Max Forecast
$15.00+26.69%

Should I buy or sell VTRS stock?

Based on 2 analysts offering ratings for Viatris Inc.
Buy
Strong Buy
1 analysts 50%
Buy
0 analysts 0%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VTRS stock forecasts and price targets.

VTRS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-07-19
lockedlocked$00.00+00.00%2024-03-28

1 of 1

Forecast return on equity

Is VTRS forecast to generate an efficient return?
Company
N/A
Industry
36.96%
Market
80.3%

Forecast return on assets

Is VTRS forecast to generate an efficient return on assets?
Company
N/A
Industry
17.48%

VTRS earnings per share forecast

What is VTRS's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$2.73
Avg 2 year Forecast
$2.69
Avg 3 year Forecast
$2.81

VTRS revenue forecast

What is VTRS's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$15.1B-1.42%
Avg 2 year Forecast
$15.3B-0.25%
Avg 3 year Forecast
$15.4B-0.07%
VTRS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VTRS revenue growth forecast

How is VTRS forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
-0.02%
Industry
7.64%
Market
11.24%
VTRS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VTRS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VTRS vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
VTRS$11.84$14.00+18.24%Buy
NBIX$145.69$165.50+13.60%Strong Buy
RDY$78.12$81.00+3.69%Strong Buy
CTLT$57.91$63.38+9.44%Hold
TEVA$16.81$19.14+13.88%Strong Buy

Viatris Stock Forecast FAQ

Is Viatris Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: VTRS) stock is to Buy VTRS stock.

Out of 2 analysts, 1 (50%) are recommending VTRS as a Strong Buy, 0 (0%) are recommending VTRS as a Buy, 1 (50%) are recommending VTRS as a Hold, 0 (0%) are recommending VTRS as a Sell, and 0 (0%) are recommending VTRS as a Strong Sell.

If you're new to stock investing, here's how to buy Viatris stock.

What is VTRS's earnings growth forecast for 2024-2026?

(NASDAQ: VTRS) Viatris's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 20.18%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.64%.

Viatris's earnings in 2024 is -$56,100,000.On average, 3 Wall Street analysts forecast VTRS's earnings for 2024 to be $3,254,474,216, with the lowest VTRS earnings forecast at $3,226,731,469, and the highest VTRS earnings forecast at $3,298,172,019. On average, 3 Wall Street analysts forecast VTRS's earnings for 2025 to be $3,202,917,953, with the lowest VTRS earnings forecast at $3,083,850,371, and the highest VTRS earnings forecast at $3,286,265,260.

In 2026, VTRS is forecast to generate $3,339,845,672 in earnings, with the lowest earnings forecast at $3,286,265,260 and the highest earnings forecast at $3,393,426,084.

What is VTRS's revenue growth forecast for 2024-2026?

(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of -0.02% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.24%.

Viatris's revenue in 2024 is $15,361,200,000.On average, 1 Wall Street analysts forecast VTRS's revenue for 2024 to be $18,030,082,444,646, with the lowest VTRS revenue forecast at $18,030,082,444,646, and the highest VTRS revenue forecast at $18,030,082,444,646. On average, 2 Wall Street analysts forecast VTRS's revenue for 2025 to be $18,243,582,525,751, with the lowest VTRS revenue forecast at $18,047,287,710,230, and the highest VTRS revenue forecast at $18,439,877,341,271.

In 2026, VTRS is forecast to generate $18,277,106,003,435 in revenue, with the lowest revenue forecast at $18,151,364,683,569 and the highest revenue forecast at $18,402,847,323,300.

What is VTRS's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: VTRS) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 17.48%.

What is VTRS's Price Target?

According to 2 Wall Street analysts that have issued a 1 year VTRS price target, the average VTRS price target is $14.00, with the highest VTRS stock price forecast at $15.00 and the lowest VTRS stock price forecast at $13.00.

On average, Wall Street analysts predict that Viatris's share price could reach $14.00 by Jul 19, 2025. The average Viatris stock price prediction forecasts a potential upside of 18.24% from the current VTRS share price of $11.84.

What is VTRS's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: VTRS) Viatris's current Earnings Per Share (EPS) is -$0.03. On average, analysts forecast that VTRS's EPS will be $2.73 for 2024, with the lowest EPS forecast at $2.71, and the highest EPS forecast at $2.77. On average, analysts forecast that VTRS's EPS will be $2.69 for 2025, with the lowest EPS forecast at $2.59, and the highest EPS forecast at $2.76. In 2026, VTRS's EPS is forecast to hit $2.81 (min: $2.76, max: $2.85).

What is VTRS's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: VTRS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.